With your own knowledge and the help of the following document:

Document 1 (Title: Post-translational Regulation of Protein Homeostasis): Protein degradation represents a crucial regulatory mechanism for maintaining cellular homeostasis, controlling quality of protein folding, and regulating the abundance of regulatory proteins. The ubiquitin-proteasome system (UPS) constitutes the principal non-lysosomal proteolytic pathway in eukaryotic cells, responsible for the selective degradation of approximately 80-90% of cellular proteins. The process involves sequential attachment of multiple ubiquitin molecules to target proteins, marking them for recognition and degradation by the 26S proteasome complex. Ubiquitination proceeds through a three-enzyme cascade involving E1 (ubiquitin-activating), E2 (ubiquitin-conjugating), and E3 (ubiquitin ligase) enzymes, culminating in the formation of an isopeptide bond between the C-terminal glycine of ubiquitin and lysine residues on the target protein. Subsequent ubiquitin molecules attach to lysine residues within the previously conjugated ubiquitin, forming polyubiquitin chains with distinct linkage patterns that determine the fate of the tagged protein. Commonly, K48-linked polyubiquitin chains signal proteasomal degradation, while K63-linked chains often mediate non-proteolytic signaling functions. The 26S proteasome represents a large, barrel-shaped multi-catalytic complex comprising a 20S core particle containing proteolytic sites and a 19S regulatory particle responsible for substrate recognition, deubiquitination, unfolding, and translocation. This cylindrical architecture sequesters proteolytic activity within an internal chamber, preventing indiscriminate protein degradation. Upon recognition of polyubiquitinated substrates, the proteasome removes the ubiquitin tags (which are recycled), unfolds the protein substrate through ATP-dependent processes, and progressively degrades it into short peptides and individual amino acids. Dysregulation of this system has been implicated in various pathological states, including neurodegenerative diseases, cancer, and inflammatory disorders, highlighting its fundamental importance in cellular physiology.
Document 2 (Title: Toxin-Mediated Bacterial Diseases and Immunoprophylaxis): Diphtheria, caused by toxigenic strains of Corynebacterium diphtheriae, represents a paradigmatic toxin-mediated bacterial disease with distinctive pathophysiological mechanisms and immunological considerations. While relatively uncommon in developed nations due to widespread immunization, the disease remains endemic in regions with suboptimal vaccination coverage, presenting substantial morbidity and mortality, particularly in pediatric populations. The pathogenesis centrally involves exotoxin production by C. diphtheriae strains lysogenized with a bacteriophage carrying the tox gene. The diphtheria toxin, a single polypeptide comprising two functional domains, initially binds to cell surface receptors via its B-fragment, facilitating entry of the catalytic A-fragment into the cytoplasm. The A-fragment catalyzes ADP-ribosylation of elongation factor 2, irreversibly inhibiting protein synthesis and inducing cellular apoptosis. Local infection typically manifests as a distinctive gray-white pseudomembranous pharyngitis with regional lymphadenopathy, while toxin-mediated systemic complications include myocarditis and peripheral neuropathy, which account for the majority of fatalities. Immunization against diphtheria utilizes formaldehyde-treated toxin (toxoid) to induce neutralizing antibodies directed against the B-fragment, preventing cellular binding and internalization. This humoral immunity, mediated by circulating IgG antibodies, provides effective protection against toxin-mediated manifestations but does not prevent colonization by toxigenic strains. Protective efficacy correlates directly with antitoxin antibody titers, with levels exceeding 0.01 IU/mL considered protective. The conventional immunization schedule includes primary series administration during infancy followed by periodic boosters to maintain protective antibody levels throughout life. In contrast to cellular immunity (mediated by CD4+ T lymphocytes) or mucosal protection (mediated by secretory IgA), which play predominant roles in defense against intracellular pathogens and mucosal colonizers respectively, protection against diphtheria principally relies on circulating neutralizing antibodies interfering with toxin-receptor interaction. Unimmunized or inadequately immunized individuals remain susceptible to both localized disease and potentially lethal systemic complications through toxin dissemination.
Document 3 (Title: Antiviral Strategies Against Orthomyxoviruses): Influenza viruses, belonging to the Orthomyxoviridae family, cause substantial seasonal morbidity and mortality worldwide, with periodic pandemic potential through antigenic shift events. These enveloped, negative-sense, segmented RNA viruses demonstrate a complex replication cycle offering multiple potential targets for therapeutic intervention. The viral surface presents two major glycoproteins: hemagglutinin (HA), mediating host cell attachment and membrane fusion, and neuraminidase (NA), facilitating viral release and spread. Current antiviral strategies target distinct phases of the viral replication cycle, with neuraminidase inhibitors representing the predominant class of clinically approved agents. Viral neuraminidase functions as a sialidase, cleaving sialic acid residues from both viral and cellular glycoproteins. This enzymatic activity proves essential during the viral release phase, preventing virion aggregation and facilitating dissemination to adjacent cells. Without functional neuraminidase, newly formed virions remain tethered to the infected cell surface and to each other, substantially limiting viral spread. Neuraminidase inhibitors, including oseltamivir (oral), zanamivir (inhaled), and peramivir (intravenous), are structural analogs of sialic acid that competitively bind the enzyme's active site with high specificity and affinity. These agents demonstrate activity against both influenza A and B viruses, though effectiveness varies with viral strain and timing of administration. Clinical efficacy is maximized when treatment begins within 48 hours of symptom onset, reducing symptom duration by approximately 24-36 hours and potentially decreasing complication rates. Alternative antiviral approaches include M2 ion channel inhibitors (amantadine, rimantadine), which block viral uncoating but demonstrate limited utility due to widespread resistance and ineffectiveness against influenza B. More recently developed agents target viral RNA-dependent RNA polymerase, including baloxavir marboxil, which inhibits cap-dependent endonuclease activity essential for viral transcription initiation. Unlike direct-acting antivirals targeting viral proteases or host-encoded proteases essential for viral protein processing, neuraminidase inhibitors do not interfere with proteolytic events but rather disrupt the final phase of the viral replication cycle, offering a distinct mechanistic approach to influenza management.

Answer the following multiple-choice question.
Question: An investigator is studying the modification of newly formed polypeptides in plated eukaryotic cells. After the polypeptides are released from the ribosome, a chemically-tagged protein attaches covalently to lysine residues on the polypeptide chain, forming a modified polypeptide. When a barrel-shaped complex is added to the cytoplasm, the modified polypeptide lyses, resulting in individual amino acids and the chemically-tagged proteins. Which of the following post-translational modifications has most likely occurred?
Options:
A. Glycosylation
B. Phosphorylation
C. Carboxylation
D. Ubiquitination

Respond strictly in valid JSON format as follows:
{"answer_choice": "A"} ‚Üê if A is the answer
Output only the JSON object. Do not include any explanation, commentary, markdown, or extra text.